Marshall Wace’s Jasper Therapeutics JSPR Stock Holding History

Marshall Wace’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$40.2K	Buy	+45,656	New	+$63.4K	﹤0.01%	3000
2025 Q3	–	Sell	-50,686	Closed	-$281K	–	3152
2025 Q2	$281K	Buy	+50,686	New	+$250K	﹤0.01%	2347
2025 Q1	–	Sell	-77,722	Closed	-$1.66M	–	2873
2024 Q4	$1.66M	Buy	77,722 +11,397	+17%	+$237K	﹤0.01%	1521
2024 Q3	$1.25M	Buy	+66,325	New	+$1.32M	﹤0.01%	1558
2024 Q2	–	Sell	-13,449	Closed	-$395K	–	2744
2024 Q1	$395K	Buy	+13,449	New	+$239K	﹤0.01%	2019

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Marshall Wace's JSPR Position: Q1 2026 in Review

Marshall Wace opened a new position in Jasper Therapeutics (JSPR) in Q1 2026: 45,656 shares worth $40.2K. The stake represents ﹤0.01% of the portfolio and ranks #3000 among its holdings. This is a return to the name: Marshall Wace previously reported a position in JSPR as recently as Q2 2025.

Marshall Wace first reported a position in JSPR in Q1 2024 and has held it in 5 quarters since. The position peaked at $1.66M in Q4 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

Marshall Wace held 45,656 shares of Jasper Therapeutics worth $40.2K as of Q1 2026.
Jasper Therapeutics was a new Marshall Wace position in Q1 2026.
Jasper Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #3000 holding.
Marshall Wace first reported a position in Jasper Therapeutics in Q1 2024 and has held it in 5 quarters since.
Marshall Wace's Jasper Therapeutics position peaked at $1.66M in Q4 2024.
58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.